Brief: Kiniksa Pharmaceuticals Q2 EPS USD 0.21
25/07/2023 12:30
Jul 25 (Reuters) - Kiniksa Pharmaceuticals Q2 operating expenses USD 74.627 million. * Q2 net income USD 14.972 million * Q2 pretax profit USD -1.239 million * Q2 product revenue USD 54.495 million
Recent news on Kiniksa Pharmaceuticals International
See all newsKiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises
Kiniksa Q4 revenue rises on ARCALYST sales